Carol Gallagher

Therapeutics & Diagnostics Co-Chair

Carol Gallagher is the immediate past president and CEO of Calistoga Pharmaceuticals which developed a portfolio of delta-selective PI3 kinase inhibitors for the treatment of patients with cancer and inflammatory diseases. Gallagher joined Calistoga Pharmaceuticals in September 2008. During her tenure as CEO, Gallagher raised $80M in venturing financing, securing top-tier investors Frazier Healthcare, Alta Partners, Three Arch Venutres, Amgen Ventures, Quogue Capital, and Latterell Venture Partners. She advanced their lead molecule, CAL-101, into full development and secured a successful exit with the $600M acquisition by Gilead Sciences in April, 2011. Gallagher has over 22 years of experience in commercial and drug development roles at large and small biopharmaceutical companies.